|
Aug 18
|
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts
|
|
Aug 8
|
Travere Therapeutics price target raised to $32 from $30 at Wedbush
|
|
Aug 6
|
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
|
|
Aug 6
|
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 6
|
Travere: Q2 Earnings Snapshot
|
|
Aug 6
|
Travere Therapeutics Reports Second Quarter 2025 Financial Results
|
|
Jul 31
|
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
|
Jul 30
|
Travere Therapeutics to Report Second Quarter 2025 Financial Results
|
|
Jul 11
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 24
|
Travere Therapeutics Kicks Off “Play It Forward” Campaign for FSGS Awareness
|
|
May 23
|
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
|
|
Mar 14
|
High Growth Tech Stocks In The US With Promising Potential
|
|
Feb 24
|
Travere Therapeutics to Participate at Upcoming Investor Conferences
|
|
Feb 22
|
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
|
|
Feb 22
|
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 20
|
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 14
|
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently
|
|
Feb 13
|
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 13
|
Travere Therapeutics price target raised to $32 from $27 at Scotiabank
|
|
Feb 11
|
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
|